1. Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Results of the randomized PORTEC-2 trial
- Author
-
Annerie Slot, L.C.H.W. Lutgens, Carien L. Creutzberg, Vthbm Smit, Jan Willem M. Mens, I.M. Jürgenliemk-Schulz, J.J. Jobsen, Remi A. Nout, Hein Putter, and E. Van der Steen-Banasik
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Endometrial cancer ,medicine.medical_treatment ,High intermediate risk ,medicine.disease ,Surgery ,law.invention ,Oncology ,Randomized controlled trial ,Quality of life ,law ,medicine ,Vaginal brachytherapy ,External beam radiotherapy ,Radiology ,Stage (cooking) ,business ,Pelvic radiotherapy - Abstract
LBA5503 Background: Pelvic external beam radiotherapy (EBRT) reduces the risk of vaginal and pelvic recurrence for stage I endometrial carcinoma (EC), but without survival benefit. In the PORTEC1-trial, the 5-year risk of vaginal and pelvic recurrence for high- intermediate risk patients was 19% without further treatment, compared to 5% after EBRT. Most recurrences were located in the upper vagina. Phase II trials suggested vaginal brachytherapy (VBT) to be as effective as EBRT. PORTEC-2 is the first randomized trial comparing the efficacy of VBT and EBRT to determine which treatment provides optimal local control with best quality of life. Methods: The PORTEC-2 trial was a multicenter phase-III trial. After surgery, patients were randomly allocated (1:1) to pelvic EBRT (46 Gy in 23 fractions) or VBT (21 Gy HDR in 3 fractions, or 30 Gy LDR). Eligible patients had a high-intermediate risk EC: age > 60 and stage 1C grade 1–2 or stage 1B grade 3; any age and stage 2A grade 1–2 or grade 3 with < 50% invasion....
- Published
- 2008